Pioglitazone + Alogliptin + Alogliptin + Metformin + Dapagliflozin
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Feb 11, 2020 → Jan 16, 2024
NCT ID
NCT03499704About Pioglitazone + Alogliptin + Alogliptin + Metformin + Dapagliflozin
Pioglitazone + Alogliptin + Alogliptin + Metformin + Dapagliflozin is a approved stage product being developed by Celltrion for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT03499704. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03499704 | Approved | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2